Shire bets big on rare diseases
20 January 2016 | By Black Swan Analysis
Speciality pharma firm Shire has agreed to buy Baxalta for around $32 billion (£22 billion), to further expand its portfolio of treatments for rare diseases...
List view / Grid view
News
Trial of IMCgp100, durvalumab and tremelimumab in melanoma starts
20 January 2016 | By Victoria White
Immunocore has announced the start of the Phase Ib/II combination trial evaluating IMCgp100 with durvalumab and tremelimumab for the treatment of metastatic cutaneous melanoma...
Lilly and Incyte submit NDA for baricitinib to the FDA
Lilly and Incyte have announced the submission of a new drug application (NDA) to the US Food and Drug Administration (FDA) for the approval of oral once-daily baricitinib for the treatment of moderately-to-severely active rheumatoid arthritis (RA).
Marketing Authorisation granted for Oncaspar as combination therapy in ALL
19 January 2016 | By Victoria White
With this authorisation, Oncaspar will provide an important treatment option for more European patients with this rapidly progressing cancer of the white blood cells...
Acorda to acquire Biotie; gains rights to tozadenant
19 January 2016 | By Victoria White
In acquiring Biotie for approximately $363 million, Acorda will obtain worldwide rights to tozadenant, an oral adenosine A2a receptor antagonist currently in Phase 3 development in Parkinson’s disease...
Hodgkin’s lymphoma treatment market to hit $1.4b by 2024, says GlobalData
19 January 2016 | By Victoria White
GlobalData says the impressive growth in the market will be attributable to label extensions for Seattle Genetics’ Adcetris and the launch of new therapies for relapse or refractory Hodgkin’s lymphoma...
Aridhia’s data platform selected by EPAD for dementia prevention project
19 January 2016 | By Victoria White
The EPAD project is a powerful research collaboration between European organisations in the public and private sectors which focuses on prevention of dementia in the early stages of the disease...
Sir Ranulph Fiennes visits Source BioScience to celebrate the launch of the world’s first -70°C walk-in chamber
With temperatures regularly reaching -70°C, the coldest place on earth is unsurprisingly the Antarctic. Source BioScience is now able to replicate these bone-chilling temperatures in an innovative, efficient storage solution.
Eisai’s lenvatinib receives FDA priority review
18 January 2016 | By Victoria White
The FDA has accepted for Priority Review Eisai’s supplemental New Drug Application for lenvatinib for the potential treatment of patients with renal cell carcinoma...
EC approves Benepali – the first biosimilar of Enbrel
18 January 2016 | By Victoria White
Benepali is the first etanercept biosimilar referencing Enbrel to be approved in the EU, making it the first subcutaneous anti-TNF biosimilar available there...
FDA approves Novartis’ Cosentyx for AS and PsA
18 January 2016 | By Victoria White
Cosentyx (secukinumab) is a fully human monoclonal antibody that selectively neutralizes circulating interleukin-17A (IL-17A)...
Man dies after taking part in Phase I clinical trial
18 January 2016 | By Victoria White
In a statement, The University Hospital of Rennes confirmed that five other participants in the clinical trial remain in a stable condition...
MS treatment, AHSCT, shows “remarkable” results
18 January 2016 | By Victoria White
Autologous haematopoietic stem cell transplantation (AHSCT), developed at Sheffield Teaching Hospitals, has shown 'remarkable' results in patients with MS...
Accelerate development of Cancer Immunotherapy (iOnc) drugs with new PathHunter® Checkpoint Assays from DiscoveRx
14 January 2016 | By DiscoveRx
DiscoveRx Corporation announced the expansion of its PathHunter cell-based assays portfolio with the release of PathHunter Checkpoint Assays...
Bladder cancer treatment market set to boom, says GlobalData
14 January 2016 | By Victoria White
The company states that the growth will be primarily down to the introduction of Telesta Therapeutics MCNA and Roche’s atezolizumab in 2016 and Bristol-Myers Squibb’s Opdivoin 2017...
